Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.
Source: US Top News and Analysis
Related Posts
Foreign investors pull a record $12 billion from Indian stocks, sparked by Iran war
Foreign investors are pulling out a record $12 billion from Indian equities as the Iran…
Amazon to stock Lilly’s new weight-loss pill at U.S. kiosks, offer same-day delivery
Amazon Pharmacy began delivering GLP-1 medications in 2021, but does not stock injectable versions of…
We’re pocketing gains in this rallying chipmaker to right-size the position
The stock’s 18% rally last week made it our largest position in the portfolio. Source:…